Compare KRNY & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KRNY | SLBT |
|---|---|---|
| Founded | 1884 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.6M | 644.9M |
| IPO Year | 2014 | 2025 |
| Metric | KRNY | SLBT |
|---|---|---|
| Price | $9.15 | $0.75 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | ★ 419.5K | 52.3K |
| Earning Date | 10-22-2026 | 10-26-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | ★ 35.71 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $2,580,000.00 | N/A |
| Revenue This Year | $10.19 | N/A |
| Revenue Next Year | $12.02 | N/A |
| P/E Ratio | $57.16 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $6.23 | $0.62 |
| 52 Week High | $10.24 | $6.25 |
| Indicator | KRNY | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 27.09 |
| Support Level | $8.89 | N/A |
| Resistance Level | $9.63 | $1.75 |
| Average True Range (ATR) | 0.23 | 0.15 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 32.81 | 15.42 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income from their clients.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.